Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

29.67 -0.58 (-1.92%)
Streaming Delayed Price Updated: 12:26 PM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Why AMC Entertainment Shares Are Trading Lower By 21%; Here Are 20 Stocks Moving Premarket ↗
Gainers BioNexus Gene Lab Corp. (NASDAQ: BGLC) shares gained 48.5% to $2.05 in pre-market trading after jumping 30% on Tuesday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday! 
Via InvestorPlace
News headline image
Urban Outfitters, Toll Brothers And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Preview: Arcus Biosciences's Earnings ↗
 
Via Benzinga
News headline image
Citigroup Maintains Buy Rating for Arcus Biosciences: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
News headline image
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
News headline image
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Over $59M Bet On This Communication Services Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
BJ's Wholesale Club, Verint Systems And 2 Other Stocks Insiders Are Selling ↗
The S&P 500 closed lower on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review ↗
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
News headline image
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
News headline image
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Undervalued Biotech Stocks to Buy Before They Blast Off ↗
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
News headline image
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Arcus Biosciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
News headline image
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class ↗
Roche tested its treatment in patients with liver cancer and found "meaningful" results. 
Via Investor's Business Daily
News headline image
Nasdaq Rises 1%; US Goods Trade Gap Widens In April ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 1% on Friday. Following the market opening Friday, the Dow traded up 0.87% to 33,050.97 while the NASDAQ rose 1.06% to... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Gap Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Oncorus, Inc. (NASDAQ: ONCR) shares rose 90% to $0.38 in pre-market trading after dropping around 17% on Thursday. Oncorus recently posted a narrower-than-expected quarterly loss. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.